Education
About Us
Working with TipRanks
Follow Us
Apellis Pharmaceuticals Inc (APLS)
NASDAQ:APLS
Earnings Data
Report Date
Apr 30, 2026After Close (Confirmed)
Period Ending
2026 (Q1)Consensus EPS Forecast
-0.35Last Year’s EPS
-0.74Same Quarter Last Year
Moderate Buy
Based on 14 Analysts Ratings
Earnings Call Summary
Earnings Call Sentiment|Positive
The call emphasized multiple commercial and scientific positives: robust EMPAVELI early launch metrics (>5% market penetration, 267 start forms), SYFOVRE injection growth (~17% YoY) and strong 5‑year clinical data, a progressing pipeline with upcoming readouts and regulatory milestones, and a solid cash position ($466M). Offsetting these strengths are near-term revenue headwinds from elevated free goods and high gross-to-net adjustments (mid‑to‑high‑20% range), seasonal and quarter-to-quarter variability for launches in ultra-rare populations, modestly higher 2026 operating expenses to fund pivotal trials, and a $94M convertible debt maturing in 2026. Overall, the highlights around commercial traction, data readouts, pipeline advancement and financial flexibility outweigh the challenges, though execution risks and revenue timing uncertainty remain.Company Guidance
Strong Full-Year Revenue with One-Time Benefit
Total revenue for FY2025 was $1.0 billion, which includes a one-time $275 million upfront payment from the Sobi royalty repurchase agreement that materially contributed to full-year results.
SYFOVRE Commercial Momentum — Injection Growth
SYFOVRE total injections grew approximately 17% year‑over‑year in 2025, demonstrating underlying demand and resilience despite revenue headwinds; Q4 SYFOVRE net product revenue was $155 million and full-year net product revenue was $587 million.
Compelling 5-Year GALE Data for SYFOVRE
Post-hoc 5-year GALE extension data showed SYFOVRE delayed progression of geographic atrophy by approximately 1.5 years in nonsubfoveal GA versus sham, supporting long-term clinical benefit and differentiation.
EMPAVELI Early Launch Outperformance
EMPAVELI achieved more than 5% market penetration after its first full quarter on the market, reported U.S. net product revenue of $35 million in Q4 and $102 million for FY2025, and accumulated 267 cumulative patient start forms by year-end, signaling strong early uptake.
Broad Payer Coverage for EMPAVELI
Published payer policies reimburse EMPAVELI to label or with minimal restrictions for approximately 95% of policies, supporting access and adoption.
Durable Market Position in Geographic Atrophy
SYFOVRE continues to lead the GA market with roughly 60% market share and is supported by extensive clinical and real-world evidence (including 5-year data), preferred payer status and initiatives to improve workflow and adoption.
Pipeline Advancement and Milestones
Key pipeline progress: pivotal trials underway for EMPAVELI in FSGS and DGF; Phase II combo (SYFOVRE + APL-3007) ongoing with topline expected in 2027; IND for APL-9099 (FcRn base editing) planned in H2 2026; prefilled syringe regulatory submission targeted in H1 2026; OCT-F research availability planned H2 2026.
Scientific and Publication Recognition
EMPAVELI data published in the New England Journal of Medicine and multiple oral presentations at Macula Society and other conferences reinforce clinical credibility and physician receptivity.
Solid Cash Position and Financial Flexibility
Cash and cash equivalents of $466 million at year-end 2025, supporting near-term operations and self-funding ambitions for the pipeline while providing flexibility to address capital needs.
APLS Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed
APLS Earnings-Related Price Changes
Report Date | Price 1 Day Before | Price 1 Day After | Percentage Change |
|---|---|---|---|
Feb 24, 2026 | $22.47 | $22.13 | -1.51% |
Oct 30, 2025 | $30.05 | $20.73 | -31.01% |
Jul 31, 2025 | $19.00 | $22.34 | +17.58% |
May 07, 2025 | $19.12 | $17.99 | -5.91% |
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.
FAQ
When does Apellis Pharmaceuticals Inc (APLS) report earnings?
Apellis Pharmaceuticals Inc (APLS) is schdueled to report earning on Apr 30, 2026, After Close (Confirmed).
What is Apellis Pharmaceuticals Inc (APLS) earnings time?
Apellis Pharmaceuticals Inc (APLS) earnings time is at Apr 30, 2026, After Close (Confirmed).
Where can I see when companies are reporting earnings?
You can see which companies are reporting today on our designated earnings calendar.
What companies are reporting earnings today?
You can see a list of the companies which are reporting today on TipRanks earnings calendar.
What is APLS EPS forecast?
APLS EPS forecast for the fiscal quarter 2026 (Q1) is -0.35.